These significant results have led to the inclusion of SGLT2 inhibitors in the European Society of Cardiology’s 2021 guidelines for heart failure treatment, as an add-on to classic therapy with angiotensin-converting enzyme inhibitors/angiotensin–receptor–neprilysin inhibitors (ACEI/ARNI), beta-blockers or mineralocorticoid receptor antagonists (MRA) [36]. Here, NR3C2 is linked to heart failure.